Literature DB >> 27772789

Neuropsychiatric characteristics of GBA-associated Parkinson disease.

Matthew Swan1, Nancy Doan2, Robert A Ortega2, Matthew Barrett3, William Nichols4, Laurie Ozelius5, Jeannie Soto-Valencia2, Sarah Boschung2, Andres Deik6, Harini Sarva7, Jose Cabassa8, Brooke Johannes2, Deborah Raymond2, Karen Marder9, Nir Giladi10, Joan Miravite2, William Severt2, Rivka Sachdev2, Vicki Shanker2, Susan Bressman2, Rachel Saunders-Pullman11.   

Abstract

Mutations in GBA1 are a well-established risk factor for Parkinson disease (PD). GBA-associated PD (GBA-PD) may have a higher burden of nonmotor symptoms than idiopathic PD (IPD). We sought to characterize the relationship between GBA-PD and neuropsychiatric symptoms. Subjects were screened for common GBA1 mutations. GBA-PD (n=31) and non-carrier (IPD; n=55) scores were compared on the Unified Parkinson Disease Rating Scale (UPDRS), Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI), and the State-Trait Anxiety Index (STAI). In univariate comparisons, GBA-PD had a greater prevalence of depression (33.3%) versus IPD (13.2%) (p<0.05). In regression models controlling for age, sex, disease duration, motor disability, and MoCA score, GBA-PD had an increased odds of depression (OR 3.66, 95% CI 1.13-11.8) (p=0.03). Post-hoc analysis stratified by sex showed that, among men, GBA-PD had a higher burden of trait anxiety and depression than IPD; this finding was sustained in multivariate models. Among women, GBA-PD did not confer greater psychiatric morbidity than IPD. These results suggest that GBA1 mutations confer greater risk of neuropsychiatric morbidity in PD, and that sex may affect this association.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anxiety; Depression; GBA1; Glucocerebrosidase; Parkinson disease

Mesh:

Substances:

Year:  2016        PMID: 27772789      PMCID: PMC5268078          DOI: 10.1016/j.jns.2016.08.059

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  69 in total

Review 1.  Nonmotor symptoms in genetic Parkinson disease.

Authors:  Meike Kasten; Lena Kertelge; Norbert Brüggemann; Joyce van der Vegt; Alexander Schmidt; Vera Tadic; Carsten Buhmann; Susanne Steinlechner; Maria Isabel Behrens; Alfredo Ramirez; Ferdinand Binkofski; Hartwig Siebner; Heiner Raspe; Johann Hagenah; Rebekka Lencer; Christine Klein
Journal:  Arch Neurol       Date:  2010-06

2.  Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease.

Authors:  Tomoko Oeda; Atsushi Umemura; Yuko Mori; Satoshi Tomita; Masayuki Kohsaka; Kwiyoung Park; Kimiko Inoue; Harutoshi Fujimura; Hiroshi Hasegawa; Hiroshi Sugiyama; Hideyuki Sawada
Journal:  Neurobiol Aging       Date:  2015-09-07       Impact factor: 4.673

3.  Factors associated with depression in Parkinson's disease.

Authors:  Nadeeka N W Dissanayaka; Anna Sellbach; Peter A Silburn; John D O'Sullivan; Rodney Marsh; George D Mellick
Journal:  J Affect Disord       Date:  2011-02-26       Impact factor: 4.839

Review 4.  Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.

Authors:  S Pablo Sardi; Seng H Cheng; Lamya S Shihabuddin
Journal:  Prog Neurobiol       Date:  2015-01-06       Impact factor: 11.685

5.  Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease.

Authors:  Oliver Riedel; Jens Klotsche; Annika Spottke; Günther Deuschl; Hans Förstl; Fritz Henn; Isabella Heuser; Wolfgang Oertel; Heinz Reichmann; Peter Riederer; Claudia Trenkwalder; Richard Dodel; Hans-Ulrich Wittchen
Journal:  J Neurol       Date:  2010-02-06       Impact factor: 4.849

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

8.  Psychopathology at initial diagnosis in dementia with Lewy bodies versus Alzheimer disease: comparison of matched groups with autopsy-confirmed diagnoses.

Authors:  E Rockwell; J Choure; D Galasko; J Olichney; D V Jeste
Journal:  Int J Geriatr Psychiatry       Date:  2000-09       Impact factor: 3.485

9.  Screening for anxiety symptoms in Parkinson disease: a cross-sectional study.

Authors:  Elka Stefanova; Ljubomir Ziropadja; Mirjana Petrović; Tanja Stojković; Vladimir Kostić
Journal:  J Geriatr Psychiatry Neurol       Date:  2013-02-13       Impact factor: 2.680

10.  Parkinson's disease and anxiety: comorbidity with depression.

Authors:  M A Menza; D E Robertson-Hoffman; A S Bonapace
Journal:  Biol Psychiatry       Date:  1993-10-01       Impact factor: 13.382

View more
  17 in total

1.  Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers.

Authors:  Eileen E Moran; Cuiling Wang; Mindy Katz; Laurie Ozelius; Alison Schwartz; Jelena Pavlovic; Roberto A Ortega; Richard B Lipton; Molly E Zimmerman; Rachel Saunders-Pullman
Journal:  Neurobiol Aging       Date:  2017-06-24       Impact factor: 4.673

Review 2.  Therapy of Parkinson's Disease Subtypes.

Authors:  Connie Marras; K Ray Chaudhuri; Nataliya Titova; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

3.  High mobility group box protein 1 downregulates acid β-glucosidase 1 in synovial fibroblasts from patients with rheumatoid arthritis.

Authors:  Bin Zhang; Hongzhi Wang; Yiwen Wang; Mingfeng Yang; Juanfang Gu; Ming Yao
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

4.  Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.

Authors:  Tanya Simuni; Michael C Brumm; Liz Uribe; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; Roy N Alcalay; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Kelly Nudelman; Duygu Tosun-Turgut; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha Hutten; Susan Bressman; Kenneth Marek
Journal:  Mov Disord       Date:  2020-02-19       Impact factor: 10.338

5.  LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease.

Authors:  Yuri L Sosero; Eric Yu; Lynne Krohn; Uladzislau Rudakou; Kheireddin Mufti; Jennifer A Ruskey; Farnaz Asayesh; Sandra B Laurent; Dan Spiegelman; Stanley Fahn; Cheryl Waters; S Pablo Sardi; Sara Bandres-Ciga; Roy N Alcalay; Ziv Gan-Or; Konstantin Senkevich
Journal:  Neurobiol Aging       Date:  2021-02-28       Impact factor: 5.133

6.  Whole genome sequence analyses of brain imaging measures in the Framingham Study.

Authors:  Chloé Sarnowski; Claudia L Satizabal; Charles DeCarli; Achilleas N Pitsillides; L Adrienne Cupples; Ramachandran S Vasan; James G Wilson; Joshua C Bis; Myriam Fornage; Alexa S Beiser; Anita L DeStefano; Josée Dupuis; Sudha Seshadri
Journal:  Neurology       Date:  2017-12-27       Impact factor: 9.910

Review 7.  The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease.

Authors:  Alexia Polissidis; Lilian Petropoulou-Vathi; Modestos Nakos-Bimpos; Hardy J Rideout
Journal:  Biomolecules       Date:  2020-06-16

8.  The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders.

Authors:  David J Irwin; Howard I Hurtig
Journal:  J Alzheimers Dis Parkinsonism       Date:  2018-08-10

Review 9.  A Meta-Analysis of GBA-Related Clinical Symptoms in Parkinson's Disease.

Authors:  Yuan Zhang; Li Shu; Xun Zhou; Hongxu Pan; Qian Xu; Jifeng Guo; Beisha Tang; Qiying Sun
Journal:  Parkinsons Dis       Date:  2018-09-27

Review 10.  Profiling Non-motor Symptoms in Monogenic Parkinson's Disease.

Authors:  Xinyao Liu; Weidong Le
Journal:  Front Aging Neurosci       Date:  2020-10-30       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.